{
  "id": 15773500,
  "title": "Long-Term MINT Data Support Durable Response to Inebilizumab in Myasthenia Gravis",
  "url": "https://urgent.news/2026/10/20/long-term-mint-data-support-durable-response-to-inebilizumab-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-20T16:27:56.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/aanemvideopearls/123480"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- One-year results from the open-label extension of the phase III MINT trial presented at the American Association of Neuromuscular and Electrodiagnostic Medicine annual meeting showed that the benefits of inebilizumab (Uplizna...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}